Floatz logo

cc-5013

Recurrent Childhood Pineoblastoma

National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Childhood Pineoblastoma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 1CCC
Irinotecan
National Cancer Institute (NCI)
Phase 1/2CCC
AZD1775
National Cancer Institute (NCI)
Phase 1/2CCC
Vorinostat
National Cancer Institute (NCI)
Phase 1CCC

View all 17 →

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →